Uncategorized

Children and COVID19: State Level Data Report | Placental Tissue Destruction and Insufficiency from COVID-19 Causes Stillbirth and Neonatal Death from Hypoxic-Ischemic Injury: A Study of 68 Cases with SARS-CoV-2 Placentitis from 12 Countries | Thromboprophylaxis in Patients with COVID-19. A Brief Update to the CHEST Guideline and Expert Panel Report | Azithromycin in patients with COVID-19: a systematic review and meta-analysis | Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19–Associated Hospitalization in Infants Aged <6 Months — 17 States, July 2021–January 2022

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods | Children and COVID19: State Level Data Report
| Safety, tolerability and viral kinetics during SARS-CoV-2 viral challenge
| Long-term cardiovascular outcomes of COVID-19 | FDA to discuss request authorization for the Pfizer COVID-19 Vaccine for use in children 6 months-4 years | mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits comparable B cell expansion, neutralizing antibodies and protection against Omicron | Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2

Children and COVID19: State Level Data Report | Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant | Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods | Associations between adverse childhood experiences, attitudes towards COVID-19 restrictions and vaccine hesitancy: a cross-sectional study | U.S. FDA approves the Moderna COVID-19 Vaccine (Spikevax) for the prevention of COVID-19 in individuals 18 years of age and older | Novavax Submitted a Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods — United States, December 2020–January 2022 | Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C | Viral Interference between Respiratory Viruses | Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–

COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021 | SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland | Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a cross-sectional study of patients tested between March 2020 and November 2021 | Ancestral SARS-CoV-2-specific T cells cross-recognize Omicron | Effectiveness of BNT162b2 COVID-19 booster vaccine against covid-19 related symptoms and hospitalization in England

Children and COVID19: State Level Data Report | Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron – Retrospective Cohort Study | Infectious viral load in unvaccinated and vaccinated patients infected with SARS-CoV-2 WT, Delta and Omicron | Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021 | Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts

COVID-19: State-Level Data Report | Characteristics and Clinical Outcomes of Children and Adolescents Aged <18 years hospitalized with covid-19 – six hospitals, united states, july-august 2021 | characteristics and outcomes of patients in south africa during the omicron wave compared previous waves cdc advisory committee on immunization practices panel endorsed pfizer biontech’s covid booster shots for 12 to 15-years olds risk factors severe among persons aged>18 years who completed a primary COVID19 vaccination series

CDC Updates and Shortens Recommended Isolation and Quarantine Period for General Population | Children and COVID-19: State-Level Data Report | Texas Children’s Hospital and Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization in India

Children and COVID-19: State Data Report | Duration of SARS-CoV-2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study | Quarantine and Isolation | Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19